Fusion Biologics

Executive Summary

Fusion Biologics is a private regenerative medicine company headquartered in San Diego, founded in 2015, that develops and commercializes advanced amniotic membrane products for wound care. Its portfolio includes amniotic skin grafts designed to accelerate healing, reduce scarring, and improve outcomes for chronic wounds, burns, and surgical sites. The company differentiates itself through product quality, regulatory compliance, and customer support, serving healthcare providers in a growing market driven by an aging population and rising diabetes rates. Despite a lack of publicly available financials or pipeline details, Fusion Biologics operates in the expanding biologic wound care segment, which is increasingly adopting placental-derived allografts. The main challenges include competition from established players like MiMedx and Organogenesis, and the need for robust clinical evidence to secure broader reimbursement and market share.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for diabetic foot ulcer indication60% success
• Q2 2026Strategic partnership with a national wound care distributor70% success
• Q4 2026Publication of retrospective clinical outcomes in a peer-reviewed journal80% success